Calidi Biotherapeutics Inc. to Showcase RedTail Platform and Oncology Advancements in Investor Webinar

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company, is set to host an investor webinar on July 24, 2025, at 4:15 p.m. ET. The webinar, led by CEO Eric Poma, Ph.D., will focus on the company's RedTail(TM) platform, a novel approach to treating metastatic tumors by evading immune detection. Preclinical data on Calidi's lead candidate, CLD-401, has shown promising results, including tumor elimination and the activation of immune memory. The company is moving forward with an Investigational New Drug (IND) filing and seeking strategic pharmaceutical partnerships to aid in the commercialization of its therapies. Following the presentation, there will be a Q&A session for participants. For more details, visit https://ibn.fm/zIp8d.